Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance Physician Registry

Jeffrey A Sparks MD MMSc1, Zachary S Wallace MD MSC2*, Andrea M Seet MPH3, Milena A Gianfrancesco MPH PhD3, Zara Izadi MPharm MAS3,4, Kimme L Hyrich MD PhD5, Anja Strangfeld MD PhD6, Laure Gossec MD PhD7, Loreto Carmona MD PhD8, Elsa F Mateus PhD9, Saskia Lawson-Tovey BA10, Laura Trupin MPH3, Stephanie Rush BA3, Patricia Katz PhD3, Gabriela Schmajuk MD MS3,11, Lindsay Jacobsohn BA3, Leanna Wise MD13, Emily L Gilbert MD PhD14, Ali Duarte-Garcia MD MSC15, Maria O Valenzuela-Almada MD16, Guillermo Pons-Estel MD, MSC, PhD17, Carolina A. Isnardi MD17, Guillermo A. Berbotto MD18, Tiffany Y-T Hsu MD PhD1, Kristin M D'Silva MD2, Naomi J Patel MD2, Lianne Kearsley-Fleet PhD19, Martin Schaefer PhD6, Sandra Lúcia Euzébio Ribeiro MSC PhD20, Samar Al Emadi MBBS FRCPC FACR12, Liselotte Tidblad MD21, Carlo Alberto Sciriè MD PhD22, Bernd Raffeiner MD PhD23, Thierry Thomas MD24, René-Marc Flipo MD PhD25, Jérôme Avouac MD PhD26, Raphaèle Seror MD PhD27, Miguel Bernardes MD PhD28, Maria Margarida Cunha MD29, Rebecca Hassels MD30, Hendrik Schulze-Koops MD PhD31, Ulf Müller-Ladner30, Christof Specker MD32, Viviane Angelina de Souza MD33, Licia Maria Henrique da Mota MD34, Ana Paula Monteiro Gomides MD35, Philippe Dieude MD PhD36, Elena Nikiphorou MD PhD37, Vanessa L Kronzer MD MSC16, Namrata Singh MD MSC38, Manuel F Ugarte-Gil MD, MSC39, Beth Wallace MD MSC40, Akpabio Akpabio MD FMCP41, Ranjeny Thomas MBBS MD42, Suleman Bhana MD FACR43, Wendy Costello44, Rebecca Grainger MBChB BMedSci PhD45, Jonathan S Hausmann MD46, Jean W Liew MD MS47, Emily Sirotich BSc48, Paul Sufka MD49, Philip C Robinson MBChB PhD50, Pedro M Machado MD PhD51, Jinoos Yazdany MD MPH3, on behalf of the COVID-19 Global Rheumatology Alliance

*Contributed equally.

1 Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
2 Clinical Epidemiology Program and Rheumatology Unit, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
3 Division of Rheumatology, Department of Medicine, University of California, San Francisco
4 Department of Epidemiology and Biostatistics, University of California, San Francisco
5 Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom; National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
6 German Rheumatism Research Center (DRFZ Berlin), Epidemiology and Health Care Research, Berlin, Germany
7 Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Paris France; Pitié-Salpêtrière hospital, AP-HP. Sorbonne Université, Rheumatology department, Paris, France
8 Instituto de Salud Musculoesquelética, Madrid, Spain
9 Portuguese League Against Rheumatic Diseases (LPCDR), Lisbon, Portugal; European League Against Rheumatism (EULAR) Standing Committee of People with Arthritis/Rheumatism in Europe (PARE), Kilchberg, Switzerland
10 Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom; National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
11 San Francisco VA Healthcare System, San Francisco
12 Rheumatology Department, Hamad Medical Corporation, Doha -Qatar
13 Division of Rheumatology, Department of Internal Medicine, University of Southern California, Los Angeles, CA
14 Division of Rheumatology, Mayo Clinic, Jacksonville, Florida
15 Division of Rheumatology and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota
16 Division of Rheumatology, Mayo Clinic, Rochester, Minnesota
17 SAR-COVID, Argentine Society of Rheumatology, Argentina
18 Sanatorio Británico Rosario, Chief of the Rheumatology Service
19 Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK
20 Hospital Universitário Getúlio Vargas, Faculty of Medicine, Federal University of Amazonas, Brazil
21 Division of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden
22 Epidemiology Research Unit, Italian Society for Rheumatology, Milan, Italy
23 Department of Rheumatology, Central Hospital of Bolzano, Italy
24 Société Française de Rhumatologie (SFR), Department of Rheumatology, Hôpital Nord, Université de Lyon-Université Jean Monnet, Saint-Etienne, France
25 Department of Rheumatology, University of Lille, Lille, France
26 Université de Paris, Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP, Paris, France
27 Department of Rheumatology, Université Paris-Saclay, Assistance Publique, Hôpitaux de Paris, France
28 Department of Medicine, Faculty of Medicine, University of Porto; Rheumatology Department, Centro Hospitalar e Universitário de São João, Porto, Portugal
29 Rheumatology Department, Hospital Garcia de Orta, Almada
30 Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus-Liebig-University Giessen, Germany
31 Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, Ludwig-Maximilians-University Munich, Munich, Germany
32 KEM Kliniken Essen-Mitte, Department of Rheumatology and Clinical Immunology, Essen-Mitte, Germany

https://mc.manuscriptcentral.com/ard
Universidade Federal de Juiz de For a (UFJF), Brazil
Hospital Universitário de Brasília, Universidade de Brasília (HUB-UnB-EBSERH), Brasília-DF, Brazil
Centro Universitário de Brasilia (UniCEUB), Brazil
Paris University, INSERM 1152; Bichat Claude-Bernard hospital, AP-HP, Paris University, Rheumatology department, Paris, France
Centre for Rheumatic Diseases, King’s College London, London, UK & Rheumatology Department, King’s College Hospital, London, UK
Division of Rheumatology, University of Washington, WA, USA
School of Medicine, Universidad Cientifica del Sur, Lima, Peru and Rheumatology Department, Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru
Department of Internal Medicine/Rheumatology, University of Michigan, VA Ann Arbor Healthcare System Center for Clinical Management Research
Rheumatology Department, Royal Hallamshire Hospital, Sheffield, UK.
UQ Diamantina Institute, University of Queensland, Brisbane, Qld, Australia
Crystal Run Health, Middletown, NY, USA
Irish Children's Arthritis Network (iCAN)
Department of Medicine, University of Otago, Wellington, New Zealand
Program in Rheumatology, Boston Children’s Hospital; Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Section of Rheumatology, Department of Medicine, Boston University School of Medicine, Boston, MA
Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada, and Canadian Arthritis Patient Alliance, Toronto, ON, Canada
Healthpartners, St. Paul, MN, USA
University of Queensland Faculty of Medicine, Brisbane, Australia
Royal Brisbane & Women’s Hospital, Metro North Hospital & Health Service, Queensland, Australia
Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK; National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK; Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, UK

Keywords: COVID-19, rheumatoid arthritis, DMARDs, biologics

Manuscript word count: 2,849 (max 3,000)
Abstract word count: 226 (max 250)
References: 31
Tables/Figures: 4
Corresponding Authors:

Jeffrey A. Sparks, MD, MMSc
Division of Rheumatology, Inflammation, and Immunity
Brigham and Women’s Hospital
60 Fenwood Road, #6016U
Boston, MA 02115
617-525-1040
jsparks@bwh.harvard.edu
@jeffsparks

Zachary S. Wallace, MD, MSc
Clinical Epidemiology Program
Division of Rheumatology, Allergy, and Immunology
Massachusetts General Hospital
100 Cambridge Street, 16th Floor
Boston, MA 02114
617-724-2507
zswallace@mgh.harvard.edu
@zach_wallace_md
ABSTRACT

Objective: To investigate baseline use of biologic or targeted synthetic (b/ts) DMARDs and COVID-19 outcomes in rheumatoid arthritis (RA).

Methods: We analyzed the COVID-19 Global Rheumatology Alliance physician registry (24/Mar/2020 to 12/Apr/2021). We investigated b/tsDMARD use for RA at the clinical onset of COVID-19 (baseline): abatacept (ABA), rituximab (RTX), Janus kinase inhibitors (JAKi), interleukin-6 inhibitors (IL6i), or tumor necrosis factor inhibitors (TNFi, reference group). The ordinal COVID-19 severity outcome was: 1) no hospitalization, 2) hospitalization without oxygen, 3) hospitalization with oxygen/ventilation, or 4) death. We used ordinal logistic regression to estimate ORs (odds of being one level higher on the ordinal outcome) for each drug class compared to TNFi, adjusting for potential baseline confounders.

Results: Of 2,869 people with RA (mean age 56.7 years, 80.8% female) on b/tsDMARD at the onset of COVID-19, there were n=237 on ABA, n=364 on RTX, n=317 on IL6i, n=563 on JAKi, and n=1,388 on TNFi. Overall, 613 (21%) were hospitalized and 157 (5.5%) died. RTX (OR 4.15, 95%CI 3.16-5.44) and JAKi (OR 2.06, 95%CI 1.60-2.65) were each associated with worse COVID-19 severity compared to TNFi. There were no associations of ABA or IL6i with COVID-19 severity.

Conclusions: People with RA treated with RTX or JAKi had worse COVID-19 severity than those on TNFi. The strong association of RTX and JAKi use with poor COVID-19 outcomes highlights prioritisation of risk-mitigation strategies for these patients.
KEY MESSAGES

What is already known about this subject?

- A previous international registry study in the COVID-19 Global Rheumatology Alliance (C19-GRA) suggested that people with systemic rheumatic diseases on biologic or targeted synthetic (b/ts) DMARDS had lower odds of hospitalisation than those not using DMARDS.
- Previous studies reported that people with systemic rheumatic diseases using rituximab had higher odds of COVID-19-related mortality than those using alternative DMARDs such as methotrexate.

What does this study add?

- Using the C19-GRA, we analyzed people with RA using b/tsDMARD (to limit the potential for confounding) at time of COVID-19 onset and investigated an ordinal outcome that encompassed a range of COVID-19 outcomes.
- People with RA using rituximab or Janus kinase (JAK) inhibitors at COVID-19 onset were more likely to experience poor COVID-19 outcomes, ranging from hospitalisation to death, compared to tumor necrosis factor inhibitor use.

How might this impact on clinical practice or future developments?

- People using rituximab or JAK inhibitors for RA are more likely to experience poor COVID-19 outcomes and should be prioritized for risk mitigation strategies.
INTRODUCTION

The ongoing Coronavirus disease 2019 (COVID-19) pandemic has had a significant impact on patients with rheumatoid arthritis (RA), many of whom are treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs)(1). While b/tsDMARDs are important for controlling RA disease activity, their influence on COVID-19 outcomes in patients with RA remains unclear. This uncertainty has led to anxiety, social isolation due to shielding practices, and b/tsDMARDs discontinuation which may contribute to RA flares(2-4). Addressing the knowledge gaps around the influence of b/tsDMARDs on COVID-19 outcomes is a priority for people with RA and their providers.

The impact of b/tsDMARDs on COVID-19 outcomes is of particular interest since some of these medications, such as tocilizumab and baricitinib, have been studied as repurposed treatments for COVID-19. Some evidence suggests that baseline use of certain b/tsDMARDs, like tumor necrosis factor inhibitors (TNFi), for inflammatory disorders may be associated with less severe COVID-19 outcomes(5). In addition, among patients with COVID-19, treatment with interleukin (IL)-6 inhibitors and baricitinib lead to improved outcomes in some clinical trials(6-9). However, there are also concerns that baseline use of certain b/tsDMARDs, such as rituximab or abatacept, may be associated with worse COVID-19 outcomes due to impaired viral immune defenses(10, 11).

Due to sample size limitations, previous studies of b/tsDMARD use and COVID-19 outcomes have combined heterogeneous rheumatic diseases and medications and/or investigated a single outcome, such as hospitalization(5, 12). Therefore, we used
the COVID-19 Global Rheumatology Alliance (C19-GRA) physician registry to evaluate
the associations of different classes of b/tsDMARDs with a range of COVID-19
outcomes in people with RA.

METHODS

Data source and study sample assembly

People with rheumatic disease and COVID-19 from the C-19 GRA registry and
European Alliance of Associations for Rheumatology (EULAR) COVID-19 database
were included in the analyses. We included cases entered between March 24, 2020 and
April 12, 2021. The C19-GRA and EULAR databases include people with rheumatic
diseases diagnosed with COVID-19, as reported by rheumatology providers via two
international data entry portals. The details of these registries have been previously
reported(5, 12-17). We analyzed people with RA on b/tsDMARD at time of COVID-19
clinical onset. As of April 12, 2021, a total of 15,127 people with rheumatic diseases and
COVID-19 were reported. We included people with RA who were taking one of the
following medication classes: anti-CTLA4Ig (abatacept), anti-CD20 (rituximab), IL-6
inhibitors (tocilizumab, sarilumab), Janus kinase inhibitors (JAKi: tofacitinib, baricitinib,
or upadacitinib), or tumour necrosis factor inhibitors (TNFi: infliximab, etanercept,
adalimumab, certolizumab pegol, golimumab). The drug class of b/tsDMARD was
collected, rather than individual drugs. We did not include IL-1 inhibitors since these
were infrequently used for RA (n=4). Prior studies using the C19-GRA and EULAR
databases have included some patients also reported in this study, but the analyses
included in this study and observations reported are novel. In addition, follow-up for this study is more current than previous publications using these data.

Data quality was assessed by the University of California, San Francisco and the University of Manchester, UK, who both confirmed that there were no duplicates in the data entries. Due to the de-identified and non-interventional nature of the study, it was determined to be exempt by each institutional review board.

**Baseline b/tsDMARD exposures**

The exposure of interest was baseline use of a b/tsDMARD at the time of COVID-19 clinical onset. As in previous C19-GRA investigations, we included confirmed and presumptive cases of COVID-19 (5, 12, 14). We limited this analysis to users of abatacept, rituximab, IL-6i, JAKi, or TNFi to limit the cohort to patients with similar RA disease severity and minimize the impact of confounding by indication. We included b/tsDMARD users regardless of whether they also used a csDMARD or glucocorticoids but did not include people on conventional synthetic DMARDs (csDMARDs, e.g., hydroxychloroquine, methotrexate, sulfasalazine, leflunomide) monotherapy, as monotherapy may indicate less severe RA or be due to care access barriers or socioeconomic factors. TNFi users were the reference group since TNFi are the most frequently used b/tsDMARD in RA. Patients with RA who were reported to be on more than one b/tsDMARD were excluded from the analysis (n=3).

**COVID-19 outcomes**

The primary outcome of interest was a mutually exclusive ordinal COVID-19 severity outcome: 1) no hospitalization, 2) hospitalization with no oxygenation, 3)
hospitalization with any oxygenation or mechanical ventilation, and 4) death. We chose this primary outcome to estimate the association of b/tsDMARD exposure with general odds of worse COVID-19 severity rather than a single outcome. A similar outcome was developed by the World Health Organization (WHO) to capture the spectrum of disease and is used in clinical trials evaluating COVID-19 therapeutics (18). If a patient met multiple levels of the outcome, they were only included in the highest level. At the time of analysis, all patients were required to have a resolved clinical course.

Covariates

Details regarding demographics, including age, race/ethnicity, continent, and patient characteristics, including obesity, smoking, comorbidities (interstitial lung disease [ILD], history of cancer, hypertension, cardiovascular disease, chronic kidney disease/end-stage kidney disease, diabetes, non-ILD pulmonary disease), RA disease activity (as judged by the reporting physician), glucocorticoid dose for RA at the time of COVID-19 onset, and concomitant csDMARD (methotrexate, sulfasalazine, hydroxychloroquine) use were by physician report. For glucocorticoid dose, the amount of prednisone-equivalent glucocorticoid prescribed was treated as a categorical variable (none, >0 to 5 mg/day, >5 to 9 mg/day, and ≥10 mg/day). Hypertension and cardiovascular disease were collapsed as a single comorbidity due to collinearity.

Statistical analysis

We reported baseline characteristics and outcomes across the exposure categories of baseline b/tsDMARD use with descriptive statistics.
Ordinal logistic regression models were used to assess the association between each b/tsDMARD compared to TNF inhibitor use and the severity of COVID-19 on an ordinal scale in unadjusted and multivariable analyses to estimate odds ratios (OR) and 95% confidence intervals (CIs). The effect size of the ordinal outcome can be interpreted as the odds of being one level higher on the ordinal COVID-19 severity scale than the reference group. We assessed the proportional odds assumption for the ordinal regression model using the Brant test (19). Models in which the proportional odds assumption was not met, were re-fitted using the partial proportional odds model which relaxes the assumption of proportionality for offending predictors (20). We considered potential confounders known to be associated with either b/tsDMARD use or COVID-19 severity. Covariates included in multivariable models included sociodemographic features (age, sex), obesity, smoking status (ever vs. never), concomitant csDMARD use (MTX, HCQ, SSZ, or LEF), categorical glucocorticoid use/dose, categorical comorbidity count (0, 1, >2 of the following: chronic kidney insufficiency/end-stage kidney disease, diabetes, non-ILD pulmonary disease), other key comorbidities as individual variables (hypertension/cardiovascular disease, ILD, and cancer), disease activity (moderate/high vs. remission/low), continent (Europe, North America, South America, other), and calendar time (January-June 15, 2020 vs. June 16, 2020-April 12, 2021) (21). These time periods were selected based on the initial publication of the RECOVERY trial which reported a survival benefit associated with dexamethasone and influenced subsequent practice. We assumed that missing data were “missing at random.” We then performed multiple imputation five times to get pooled estimates to impute missing values for disease activity, race/ethnicity, glucocorticoid dose, smoking,
hypertension/cardiovascular disease, and comorbidity count. After imputation, we compared the distribution of imputed values to the distribution of variables before imputation to confirm that distributions were similar before and after imputation.

To confirm the robustness of our findings, we performed several sensitivity analyses. First, we excluded patients with ILD or cancer from the analysis since rituximab is commonly used in these patients, who may also be susceptible to poor COVID-19 outcomes. Second, given data showing a strong association between race/ethnicity and COVID-19 outcomes in the United States, we performed an analysis adjusting for this variable among U.S. patients in the registry. The race/ethnicity variable was categorized as White, Black, Hispanic, Asian, or Other/Mixed Race. However, for the model with IL-6 inhibitors, there were few outcomes within the race/ethnicity variable so we were unable to perform the model. Third, we used propensity score matching to further address potential confounding by indication. We estimated propensity scores for b/tsDMARD use based on age, sex, obesity, smoking, concomitant csDMARDs, glucocorticoid use/dose, number of comorbidities, disease activity, region, and calendar time. Covariate balance between each b/tsDMARD drug class and TNFi was assessed using Love plots (Supplemental Figures 1-4) which showed that most of the covariates were matched with an absolute standardized mean difference less than 0.1, denoting sufficient matching performance (22). Ordinal logistic regression was then performed after matching. Fourth, we repeated our primary analysis after excluding patients with a presumptive diagnosis of COVID-19. Presumptive cases were those that lacked one of the following: positive polymerase chain reaction (PCR) or antigen test for SARS-CoV-2, or typical chest imaging findings. Fifth, we repeated the analysis but stratified by
calendar time (before or after June 15, 2020 when RECOVERY trials results were announced) and by continent (North America or Europe) in case calendar time and geography may have influenced the results. Sixth, we used a revised version of the ordinal COVID-19 severity outcome that considered mechanical ventilation as its own category.

We then repeated our primary analyses using dichotomized outcomes rather than the ordinal COVID-19 severity scale to investigate whether there were particular outcomes driving the associations we observed. For example, we investigated whether each b/tsDMARD was associated with hospitalization (yes/no) compared to TNFi use.

We used the Brant test to assess whether the observed deviations from the ordinal logistic regression are larger than what could be attributed to chance alone. If the p-values are greater than the alpha level of 0.05, then the covariates satisfy the proportional odds assumption. This assumption states that the estimate between each pair of outcomes across the response levels regardless of the partition that we consider. For abatacept and JAK inhibitors, both age and glucocorticoid dose violated the assumption and for IL-6 inhibitors and rituximab, age, gender, and glucocorticoid dose violated the assumption. In order to address the lack of proportionality for these covariates, partial proportional odds models were run to relax this assumption for the respective covariates for each medication category (Supplemental Table 1). We found that the estimates were similar when comparing the proportional odds models and the non-proportional odds model, so we reported the model without relaxing the assumption.
Results were considered statistically significant at two-sided p<0.05. Analyses were conducted in R version 4.0.2.

RESULTS

Study sample and baseline characteristics

From a total of 6,132 RA cases reported to the registry, we identified 2,869 who were on abatacept (n=237), rituximab (n=364), IL-6i (n=317), JAKi (n=563), or TNFi (n=1,388), at time of clinical COVID-19 onset. Baseline clinical characteristics are shown in Table 1. The sample was predominantly female (80.8%) and mean age was 56.7 years (SD 13.4). Most patients were from Europe (51.8%) or North America (35.0%). Overall, 354 (12.3%) were obese, 582 (20.3%) were ever smokers, 810 (28.2%) were on glucocorticoids, 1,409 (49.1%) were on concomitant csDMARDs, and 510 (17.8%) had moderate/high RA disease activity. Among b/tsDMARD users, rituximab users were more likely than TNFi users to have ILD (11.0% vs. 1.4%) or a history of cancer (7.4% vs. 0.9%); JAKi users were slightly more likely than TNFi users to be obese (15.1% vs. 10.3%).

COVID-19 outcomes

Outcomes according to the COVID-19 severity scale are shown in Table 2. The majority of patients (78.6%) were not hospitalized, 137 (4.8%) were hospitalized without oxygenation, 319 (11.1%) were hospitalized with any oxygen or ventilation requirement, and 157 (5.5%) died. Among rituximab users, 80 (22.0%) required hospitalization with
any oxygen or ventilation and 54 (14.8%) died compared to 103 (7.4%) and 36 (2.6%) TNFi users, respectively. Among JAKi users, 86 (15.3%) were hospitalized with oxygen/ventilation and 40 (7.1%) died. Only 9 (2.8%) patients on baseline IL-6i died.

**Associations of b/tsDMARDs with COVID-19 severity**

The multivariable ordinal logistic regression model is shown in Table 3. Compared to TNFi users, rituximab users had a 4.15 (95%CI 3.40, 3.80) greater odds of worse COVID-19 severity as compared to patients taking TNFi, while JAKi users had a 2.06 (95%CI 1.60, 2.65) greater odds of worse COVID-19 severity. No significant associations were found with respect to abatacept or IL-6i compared to TNFi in the primary analysis.

**Sensitivity analyses**

Sensitivity analyses of the drug class comparisons are shown in Table 3. After excluding patients with ILD or cancer, the association between rituximab with poor COVID-19 outcomes when compared to TNFi use remained strong (OR 4.34 [95%CI 3.23, 5.82]). Among RA patients in the US, results were also similar when additionally adjusting for race/ethnicity. We also performed a propensity score matched analysis instead of multivariable ordinal logistic regression. The sample for each propensity score-matched analysis is illustrated in Supplemental Figure 5. Rituximab users (OR 3.36 [95%CI 2.11, 5.34]) and JAKi users (OR 1.56, 95%CI 1.01, 2.42) had increased COVID-19 severity compared to TNFi users in this analysis. In the propensity score-matched analysis, abatacept had an OR of 1.60 (95%CI 1.02, 2.51) for the ordinal COVID-19 severity outcome compared to TNFi. IL-6 inhibitor use was not associated
with COVID-19 severity in any of the analyses. Brant tests indicated that the proportional odds assumption did not hold for propensity score models; therefore, partial proportional odds models were used and confirmed that the effect estimates remained consistent (data not shown).

When stratified by calendar time (before or after June 15, 2020) and restricted to Europe or North America, results were similar (Supplementary Table 2).

**Individual COVID-19 outcomes**

We also performed analyses for each binary level of the COVID-19 severity scale (Table 4). Rituximab and JAKi use were each associated with an increased odds for each COVID-19 outcome compared to TNFi use. For example, rituximab use had increased odds for hospitalization (OR 4.53, 95%CI 3.32, 6.18) as well as death (OR 4.57, 95%CI 3.32, 9.01) compared to TNFi use. JAKi use was associated with all outcomes considered, including hospitalization requiring any oxygen or ventilation or death (OR 1.55, 95%CI 1.04, 2.18) and death (OR 2.04, 95%CI 1.58, 2.65) compared to TNFi. In these analyses, there were no statistically significant associations between abatacept or IL-6i use and the dichotomized outcomes when compared to TNFi use.

We considered a revised version of the ordinal outcome that included mechanical ventilation as a separate level. There were relatively few patients who survived after requiring mechanical ventilation (Supplementary Table 3). Results were similar using this revised ordinal outcome (Supplementary Tables 4-5).
DISCUSSION

Among RA patients on b/tsDMARDs at the onset of COVID-19, rituximab and JAKi users were at increased odds for worse COVID-19 outcomes compared to TNFi users. In contrast, we did not find an association between abatacept or IL-6i use with worse COVID-19 outcomes when compared to TNFi users. These observations can inform decision making for providers and patients during the ongoing COVID-19 pandemic. Given the association between rituximab and JAKi use with poor outcomes, vaccination and public health measures such as mask wearing and social distancing for COVID-19 risk mitigation remain paramount. In addition, other specific interventions (e.g., monoclonal antibody treatment) might be considered in this patients with COVID-19 exposure or early infection (23).

Our observations, which use the largest sample of individuals with RA and COVID-19 assembled to date, regarding rituximab exposure confirm findings from prior studies suggesting an association between baseline use of B cell depleting therapies and worse COVID-19 outcomes in people with rheumatic diseases(12, 24, 25) and multiple sclerosis (26). We also expand upon prior observations using the C19-GRA and EULAR databases by evaluating the association of rituximab with COVID-19 severity rather than only mortality and by using an alternative reference group (TNFi rather than methotrexate) and performing propensity score analyses to further address confounding by indication. By focusing on a single disease, we also were able to identify a novel association of JAK inhibitors with COVID-19 severity. Mechanistically, the impact of B cell depletion on antibody production would be expected to impair the immune system’s normal response to a viral infection. Indeed, the antibody response to
COVID-19 is critical for controlling the initial infection and preventing re-infection (27). We lacked details regarding the timing of rituximab exposure in relation to the COVID-19 infection or the duration of B cell depletion at the time of infection which may be particularly relevant when considering the risk of a poor outcome following rituximab exposure. It is also possible that glucocorticoids given as a pre-medication to rituximab infusions may have contributed to the increased risk of poor COVID-19 outcomes in RA patients on rituximab. While the results were robust to several sensitivity analyses, it is possible that the result could be confounded by factors such as unrecognized ILD.

Our findings are of particular interest given recent clinical trials and observational studies suggesting that IL-6i (6-8, 28-31) and JAKi (9) may improve outcomes for patients in the general population with COVID-19. We found no association of baseline IL-6i use in RA with COVID-19 severity compared to TNFi use. In contrast, while baricitinib treatment may have some benefit on time to recovery for patients with more severe COVID-19(9), we observed worse outcomes associated with baseline use of JAKi. This was also suggested in a recent population-based study investigating RA and other inflammatory joint diseases in Sweden (24). Glucocorticoids are known to have benefits when initiated for moderate-to-severe COVID-19 but are also associated with worse outcomes among those on baseline glucocorticoids at the time of infection (5, 12), though this may be explained by residual disease activity (32). Therefore, the timing of JAKi use relative to the COVID-19 disease course may explain our findings. Similar to glucocorticoids, baseline use of JAKi at time of SARS-CoV-2 infection may enhance viral reproduction and dampen a healthy immune response while JAKi initiation at clinical deterioration may dampen an aberrant systemic inflammatory
response. Alternatively, there may be relevant differences in COVID-19 outcomes depending on the type of JAKi used given that JAK inhibitors like tofacitinib, baricitinib, and upadacitinib target different JAKs. We were unable to perform analyses of each individual JAKi since these were collected as a class. While the primary analysis found no association of abatacept with COVID-19 severity, there was a statistical association in the propensity score-matched analysis. Further research is needed on the safety of abatacept for infection risk and severity since its mechanism of action may impair adaptive immune response.

Our study has a number of strengths including the international nature of the registry and large sample size. Additionally, we used an active comparator (TNFi), which was also a b/tsDMARD in a single rheumatic disease, as well as two different modeling approaches (multivariable logistic regression and propensity score matching) among other sensitivity analyses to account for confounding by indication and to confirm the robustness of our findings. Our observations expand upon prior general population and RA cohort studies that identified older age, greater comorbidity burden, and other factors associated with worse COVID-19 and must also be considered when assessing an individual’s risk.

Our study also has certain limitations. First, the GRA and EULAR registries are voluntary and require a provider to submit the details of a case, perhaps biasing our sample towards more severe cases. As such, the proportion of events reported across exposure groups may be an overestimate of that observed among all patients with RA in real world practice and should be interpreted in that context. However, the effect size estimates do have clinical interpretation in potentially identifying RA patients who could...
be susceptible to poor COVID-19 outcomes. While we designed the study to limit the potential impact of selection bias and confounding by indication by examining advanced therapies in a single rheumatic disease, it is possible that selective reporting could have varied according across different b/tsDMARD classes as the exposure of interest. This potential bias may have caused an upward deflection in the effect size estimate if more severe cases of a particular b/tsDMARD class were systematically reported compared to others, and this could contribute to the findings that we report. We further mitigated this possibility by adjusting for differences in concomitant medication use, disease activity, and comorbidities as well as performing an analysis removing patients with ILD or cancer. Our findings remained when we excluded presumptive cases of COVID-19. Second, though we were able to adjust for a number of potential confounders of our observed associations, there is the potential for residual unmeasured confounding. Analyzing only patients on b/tsDMARD may have helped minimize some unmeasured confounding related to access to care since all analyzed RA patients were able to receive these targeted medications. In addition, the consistent results observed in sensitivity analyses excluding patients with ILD or cancer who may be more likely to receive rituximab supports the robustness of our results. However, we did not have data available on RA duration or previous RA medications (e.g., previous TNFi use in patients on other classes of b/tsDMARDs), which may have affected the results. Medications were collected by DMARD class, so we were unable to compare individual medications within the same class. However, the goal of the study was to compare different biologic mechanisms of action for COVID-19 severity. Additionally, it is also possible that TNFi use may protect against severe COVID-19 outcomes. Thus, these
results should be interpreted cautiously and additional studies are needed to confirm our observed associations. Third, while we leveraged the largest cohort of rheumatic disease patients with COVID-19, a somewhat small number of outcomes of interest occurred in some subgroups which may have limited our power to detect significant differences among abatacept users, in particular. In addition, we were unable to investigate individual JAKi or TNFi. Finally, we did not examine medication changes after COVID-19 onset since this occurred after baseline and may have mediated the relationship we report. Most of the drugs have lengthy biologic effects (especially rituximab) while JAKi have short half-lives. Some clinicians may have chosen to continue IL-6 inhibitors after COVID-19 onset, as suggested by the American College of Rheumatology (32). Future studies are needed to investigate the association of medication changes with COVID-19 outcomes.

In conclusion, use of rituximab or JAKi, but not abatacept or IL-6i use, at the time of COVID-19 infection was associated with worse COVID-19 outcomes compared to TNFi among RA patients. Additional studies are warranted to confirm these observations. Strategies are needed to improve outcomes following COVID-19 RA on rituximab or JAK inhibitors.
REFERENCES


Acknowledgements: We wish to thank all rheumatology providers who entered data into the registry.

Funding: Financial support from the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR).

Disclaimer: The views expressed here are those of the authors and participating members of the COVID-19 Global Rheumatology Alliance and do not necessarily represent the views of the American College of Rheumatology (ACR), the European League Against Rheumatism (EULAR), the (UK) National Health Service (NHS), the National Institute for Health Research (NIHR), or the (UK) Department of Health, or any other organisation.

Contributors: JAS, ZSW, AS, MAG and JY had access to the study data, developed the figures and tables, and vouch for the data and analyses. AS and MAG performed the statistical analyses and contributed to data quality control, data analysis and interpretation of the data. JAS, ZSW, AMS, MAG, ZI, KLH, AS, LG, LC, EFM, SL-T, LT, SR, PK, GS, LJ, SAE, LW, ELG, AD-G, MOV-A, GP-E, CAI, GAB, TY-TH, KMD’S, NJP, PD, EN, VLK, NS, MFU-G, BW, AA, RT, SB, WC, RG, JSH, JWL, ES, PS, PCR, PMM, JY contributed to data collection, data analysis and interpretation of the data. JAS, ZSW and JY, directed the work, designed the data collection methods, contributed to data collection, data analysis and interpretation of the data, and had final responsibility for the decision to submit for publication. All authors contributed intellectual content during the drafting and revision of the work and approved the final version to be published.

Competing interests:
- JAS is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers K23 AR069688, R03 AR075886, L30 AR066953, P30 AR070253, and P30 AR072577), the Rheumatology Research Foundation (K Supplement Award and R Bridge Award), the Brigham Research Institute, and the R. Bruce and Joan M. Mickey Research Scholar Fund. Dr. Sparks has received research support from Amgen and Bristol-Myers Squibb and performed consultancy for Bristol-Myers Squibb, Gilead, Inova, Janssen, and Optum unrelated to this work.
- ZSW reports grant support from Bristol-Myers Squibb and Principia/Sanofi and performed consultancy for Viela Bio and MedPace, outside the submitted work. His work is supported by grants from the National Institutes of Health.
- AMS has no disclosures relevant to this study.
- MAG is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers K01 AR070585 and K24 AR074534 [JY]).
- ZI has no disclosures relevant to this study.
- KLH reports she has received speaker's fees from Abbvie and grant income from BMS, UCB, and Pfizer, all unrelated to this study. KLH is also supported by the NIHR Manchester Biomedical Research Centre.
- LC has not received fees or personal grants from any laboratory, but her institute works by contract for laboratories among other institutions, such as Abbvie Spain, Eisai, Gebro Pharma, Merck Sharp & Dohme España, S.A., Novartis Farmaceutica, Pfizer, Roche Farma, Sanofi, Aventis, Astellas Pharma, Actelion Pharmaceuticals España, Grünenthal GmbH, and UCB Pharma.
- LG reports research grants: Amgen, Galapagos, Janssen, Lilly, Pfizer, Sandoz, Sanofi; consulting fees: AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, UCB. all unrelated to this study.
- SLT has no disclosures relevant to this study.
- EM reports that LPCDR received support for specific activities: grants from Abbvie, Novartis, Janssen-Cilag, Lilly Portugal, Sanofi, Grünenthal S.A., MSD, Celgene, Medac, Pharmakern, GAfPA; grants and non-financial support from Pfizer; non-financial support from Grünenthal GmbH, outside the submitted work.
- AS reports grants from a consortium of 13 companies (among them AbbVie, BMS, Celltrion, Fresenius Kabi, Lilly, Mylan, Hexal, MSD, Pfizer, Roche, Samsung, Sanofi-Aventis, and UCB) supporting the German RABBIT register and personal fees from lectures for AbbVie, MSD, Roche, BMS, Pfizer, outside the submitted work.
- LT has no disclosures relevant to this study.
- SR has no disclosures relevant to this study.
- GS has no disclosures relevant to this study.
- PK has no disclosures relevant to this study.
- LJ has no disclosures relevant to this study.
- SA has no disclosures relevant to this study.
- LW has no disclosures relevant to this study.
- ELG has no disclosures relevant to this study.
- MOVA has no disclosures relevant to this study.
• AD has no disclosures relevant to this study. His work is supported by grants from the Centers for Disease Control and Prevention and the Rheumatology Research Foundation.
• TYT has no disclosures relevant to this study.
• KMD is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32-AR-007258) and Rheumatology Research Foundation.
• NJP is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32-AR-007258)
• Lianne Kearsley-Fleet reports no disclosures relevant to this study.
• Martin Schaefer has no disclosures relevant to this study.
• Sandra Lucia Euzebio Ribeiro has no disclosures relevant to this study.
• Samar Al-Emadi has no disclosures relevant to this study.
• Liselotte Tidblad has no disclosures relevant to this study.
• Carlo Alberto Scirè has no disclosures relevant to this study.
• Bernd Raffeiner has no disclosures relevant to this study.
• Thierry Thomas has no disclosures relevant to this study.
• René-Marc Flipo has no disclosures relevant to this study.
• Jérôme Avouac received honorarium from Pfizer, BMS, Sanofi, Roche, Novartis, Abbvie, Galapagos, Fresenius kabi, Nordic Pharma, Chugai, MSD not related to this study.
• Raphaele Seror received honorarium from GSK, BMS, Fresenius Kabi, Boehringer, Jansen, Amgen, Pfizer, Roche not related to this study.
• Miguel Bernardes received honorarium from Lilly, Janssen and Abbvie not related to this study.
• Maria Margarida Cunha has no disclosures relevant to this study.
• Rebecca Hasseli has no disclosures relevant to this study.
• Hendrik Schulze-Koops has no disclosures relevant to this study.
• Ulf Müller-Ladner has no disclosures relevant to this study.
• Christof Specker has no disclosures relevant to this study.
• Viviane Angelina de Souza has no disclosures relevant to this study.
• LMHM has received personal or institutional support from Abbvie, Janssen, Pfizer, UCB, Lilly and Roche; has delivered speeches at events related to this work and sponsored by Abbvie, Janssen, Pfizer, Roche, UCB, Sandoz, Angem, Boehringer - Ingelheim.
• Ana Paula Monteiro Gomides has no disclosures relevant to this study.
• PD has received research support from Bristol-Myers Squibb, Chugaii, Pfizer and performed consultancy for Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, Sanofi, Pfizer, Chugai, Roche, Janssen unrelated to this work.
• EN has no disclosures relevant to this study.
• VK has no disclosures relevant to this study.
• NS is supported by the RRF Investigator Award and the American Heart Association.
• MUG reports grant support from Janssen and Pfizer.
• BW has no disclosures relevant to this study.
• AA has no disclosures relevant to this study.
• RT has no disclosures relevant to this study.
• SB reports no competing interests related to this work. He reports non-branded consulting fees for AbbVie, Horizon, Novartis, and Pfizer (all <$10,000).
• WC has no disclosures relevant to this study.
• RG reports no competing interests related to this work. Outside of this work she reports personal and/or speaking fees from Abbvie, Janssen, Novartis, Pfizer, Cornerstones and travel assistance from Pfizer (all <$10,000).
• JSH reports no competing interests related to this work. He is supported by grants from the Rheumatology Research Foundation and has salary support from the Childhood Arthritis and Rheumatology Research Alliance. He has performed consulting for Novartis, Sobi, Biogen, all unrelated to this work (<$10,000).
• JWL has received research funding from Pfizer outside the submitted work.
• ES is a Board Member of the Canadian Arthritis Patient Alliance, a patient run, volunteer-based organization whose activities are largely supported by independent grants from pharmaceutical companies.
• PS reports no competing interests related to this work. He reports honorarium for doing social media for American College of Rheumatology journals (<$10,000).
• PMM has received consulting/speaker’s fees from Abbvie, BMS, Celgene, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Roche and UCB, all unrelated to this study (all <$10,000). PMM is supported by the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (BRC).
• PCR reports no competing interests related to this work. Outside of this work he reports personal consulting and/or speaking fees from Abbvie, Eli Lilly, Janssen, Novartis, Pfizer and UCB and travel assistance from Roche (all <$10,000).
• JY reports no competing interests related to this work. Her work is supported by grants from the National Institutes of Health (K24 AR074534 and P30 AR070155). Outside of this work, she has performed consulting for Eli Lilly, Pfizer, Aurinia and AstraZeneca.
• CAI, as a member of the SAR-COVID Registry received grants from Pfizer, Abbvie and Elea Phoenix during the conduct of the study. Outside of this work she reports speaking fees from Bristol-Myers Squibb.
• GPE, as a member of the SAR-COVID Registry received grants from Pfizer, Abbvie and Elea Phoenix during the conduct of the study. Outside of this work he reports personal consulting and/or speaking fees from Pfizer, GSK, Janssen and Sanofi (all <$10,000).
• GAB, as a member of the SAR-COVID Registry received grants from Pfizer, Abbvie and Elea Phoenix during the conduct of the study. Outside of this work he reports personal consulting and/or speaking fees from Pfizer, Janssen, Eli Lilly and Bago (all <$10,000).

Patient consent for publication: Not required.
**Ethics approval:** The C19-GRA physician-reported registry was determined “not human subjects’ research” by the UK Health Research Authority and the University of Manchester, as well as under United States Federal Guidelines assessed by the University of California San Francisco Institutional Review Board.

**Data availability statement:** Data are available upon reasonable request. Applications to access the data should be made to the C19-GRA Steering Committee.

**Patient and Public Involvement:** Patients were involved in the study related to standing members of the C19-GRA Steering Committee and included as co-authors.
Table 1. Baseline characteristics according to use of biologic or targeted synthetic disease-modifying antirheumatic drug for rheumatoid arthritis at time of COVID-19 onset.

<table>
<thead>
<tr>
<th></th>
<th>Overall n=2869</th>
<th>Abatacept n=237</th>
<th>Rituximab n=364</th>
<th>IL-6 inhibitors n=317</th>
<th>JAK inhibitors n=563</th>
<th>TNF inhibitors n=1388</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean age (years), SD</td>
<td>56.7, 13.4</td>
<td>61.4, 14.0</td>
<td>58.0, 12.9</td>
<td>56.4, 12.0</td>
<td>58.0, 12.3</td>
<td>55.2, 14.0</td>
</tr>
<tr>
<td>Female</td>
<td>2316 (80.8%)</td>
<td>188 (79.3%)</td>
<td>299 (82.1%)</td>
<td>257 (81.3%)</td>
<td>470 (83.5%)</td>
<td>1102 (79.4%)</td>
</tr>
<tr>
<td>Race/ethnicity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>1670 (69.0%)</td>
<td>78 (69.5%)</td>
<td>187 (64.5%)</td>
<td>169 (67.9%)</td>
<td>360 (73.2%)</td>
<td>829 (69.3%)</td>
</tr>
<tr>
<td>Black</td>
<td>113 (4.7%)</td>
<td>5 (3.2%)</td>
<td>14 (4.8%)</td>
<td>11 (4.4%)</td>
<td>22 (4.5%)</td>
<td>60 (5.0%)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>472 (19.5%)</td>
<td>32 (20.8%)</td>
<td>66 (22.8%)</td>
<td>46 (18.5%)</td>
<td>79 (16.1%)</td>
<td>233 (19.5%)</td>
</tr>
<tr>
<td>East Asian</td>
<td>81 (3.3%)</td>
<td>8 (5.2%)</td>
<td>10 (3.4%)</td>
<td>12 (4.8%)</td>
<td>10 (2.0%)</td>
<td>37 (3.1%)</td>
</tr>
<tr>
<td>Other</td>
<td>85 (3.3%)</td>
<td>2 (1.3%)</td>
<td>13 (4.5%)</td>
<td>11 (4.4%)</td>
<td>21 (4.3%)</td>
<td>38 (3.2%)</td>
</tr>
<tr>
<td>Continent</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Europe</td>
<td>1486 (51.8%)</td>
<td>103 (43.5%)</td>
<td>218 (59.9%)</td>
<td>183 (57.7%)</td>
<td>283 (50.3%)</td>
<td>699 (50.4%)</td>
</tr>
<tr>
<td>North America</td>
<td>1005 (35.0%)</td>
<td>105 (44.3%)</td>
<td>111 (30.5%)</td>
<td>83 (26.2%)</td>
<td>208 (36.9%)</td>
<td>498 (35.9%)</td>
</tr>
<tr>
<td>South America</td>
<td>276 (9.6%)</td>
<td>20 (8.4%)</td>
<td>23 (6.3%)</td>
<td>33 (10.4%)</td>
<td>55 (9.8%)</td>
<td>145 (10.4%)</td>
</tr>
<tr>
<td>Other</td>
<td>302 (10.5%)</td>
<td>9 (3.8%)</td>
<td>12 (3.3%)</td>
<td>18 (5.7%)</td>
<td>17 (3.0%)</td>
<td>46 (3.3%)</td>
</tr>
<tr>
<td>Comorbidity count*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>1494 (52.1%)</td>
<td>113 (47.7%)</td>
<td>161 (44.2%)</td>
<td>161 (50.8%)</td>
<td>270 (48.0%)</td>
<td>789 (56.8%)</td>
</tr>
<tr>
<td>1</td>
<td>837 (29.2%)</td>
<td>70 (29.5%)</td>
<td>119 (32.7%)</td>
<td>99 (31.2%)</td>
<td>176 (31.3%)</td>
<td>373 (26.9%)</td>
</tr>
<tr>
<td></td>
<td>Value 1</td>
<td>Value 2</td>
<td>Value 3</td>
<td>Value 4</td>
<td>Value 5</td>
<td>Value 6</td>
</tr>
<tr>
<td>------------------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td><strong>Individual comorbidities</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>983 (34.3%)</td>
<td>91 (38.4%)</td>
<td>121 (33.2%)</td>
<td>108 (34.1%)</td>
<td>221 (39.3%)</td>
<td>442 (31.8%)</td>
</tr>
<tr>
<td>Cardiovascular Disease</td>
<td>247 (8.6%)</td>
<td>29 (12.2%)</td>
<td>36 (9.9%)</td>
<td>32 (10.1%)</td>
<td>51 (9.1%)</td>
<td>99 (7.1%)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>356 (12.5%)</td>
<td>30 (12.8%)</td>
<td>54 (14.9%)</td>
<td>43 (13.6%)</td>
<td>74 (13.2%)</td>
<td>155 (11.3%)</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>98 (3.4%)</td>
<td>11 (4.7%)</td>
<td>11 (3.0%)</td>
<td>14 (4.4%)</td>
<td>22 (3.9%)</td>
<td>40 (2.9%)</td>
</tr>
<tr>
<td>Lung disease^</td>
<td>432 (15.2%)</td>
<td>41 (17.4%)</td>
<td>87 (24.0%)</td>
<td>44 (13.9%)</td>
<td>92 (16.4%)</td>
<td>168 (12.3%)</td>
</tr>
<tr>
<td>Interstitial lung disease</td>
<td>103 (3.6%)</td>
<td>15 (6.3%)</td>
<td>40 (11.0%)</td>
<td>15 (4.7%)</td>
<td>13 (2.3%)</td>
<td>20 (1.4%)</td>
</tr>
<tr>
<td>Cancer</td>
<td>40 (1.5%)</td>
<td>5 (2.5%)</td>
<td>27 (7.4%)</td>
<td>6 (2.2%)</td>
<td>5 (1.0%)</td>
<td>11 (0.9%)</td>
</tr>
<tr>
<td>Obesity</td>
<td>354 (12.3%)</td>
<td>31 (13.1%)</td>
<td>52 (14.3%)</td>
<td>43 (13.6%)</td>
<td>85 (15.1%)</td>
<td>143 (10.3%)</td>
</tr>
<tr>
<td><strong>Smoking status</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ever</td>
<td>582 (20.3%)</td>
<td>104 (43.9%)</td>
<td>70 (19.2%)</td>
<td>57 (18.0%)</td>
<td>99 (17.6%)</td>
<td>300 (21.6%)</td>
</tr>
<tr>
<td>Never</td>
<td>1369 (47.7%)</td>
<td>56 (23.6%)</td>
<td>142 (39.0%)</td>
<td>152 (47.9%)</td>
<td>262 (46.5%)</td>
<td>694 (50.0%)</td>
</tr>
<tr>
<td>Missing</td>
<td>918 (32.0%)</td>
<td>77 (32.5%)</td>
<td>137 (37.6%)</td>
<td>107 (33.8%)</td>
<td>202 (35.9%)</td>
<td>394 (28.4%)</td>
</tr>
<tr>
<td><strong>Concomitant RA medications</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any conventional synthetic DMARD</td>
<td>1409 (49.1%)</td>
<td>118 (49.8%)</td>
<td>194 (53.3%)</td>
<td>102 (32.2%)</td>
<td>228 (40.5%)</td>
<td>767 (55.3%)</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>1188 (41.4%)</td>
<td>92 (38.8%)</td>
<td>146 (40.1%)</td>
<td>91 (28.7%)</td>
<td>188 (33.4%)</td>
<td>671 (48.3%)</td>
</tr>
<tr>
<td>Sulfasalazine</td>
<td>136 (4.7%)</td>
<td>9 (3.8%)</td>
<td>26 (7.1%)</td>
<td>8 (2.5%)</td>
<td>18 (3.2%)</td>
<td>75 (5.4%)</td>
</tr>
<tr>
<td>Hydroxychloroquine</td>
<td>260 (9.1%)</td>
<td>25 (10.5%)</td>
<td>58 (15.9%)</td>
<td>18 (5.7%)</td>
<td>43 (7.6%)</td>
<td>116 (8.4%)</td>
</tr>
<tr>
<td>Leflunomide</td>
<td>176 (10.5%)</td>
<td>26 (11.0%)</td>
<td>49 (13.5%)</td>
<td>20 (6.3%)</td>
<td>29 (5.2%)</td>
<td>117 (8.4%)</td>
</tr>
<tr>
<td>Glucocorticoid dose (median, IQR)</td>
<td>5.0 (4.0, 6.0)</td>
<td>5.0 (4.0, 5.5)</td>
<td>5.0 (5.0, 7.5)</td>
<td>5.0 (4.5, 7.0)</td>
<td>5.0 (3.0, 5.0)</td>
<td>5.0 (5.0, 7.0)</td>
</tr>
<tr>
<td><strong>Categorical glucocorticoid use/dose</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No glucocorticoid use</td>
<td>1756 (61.2%)</td>
<td>120 (56.9%)</td>
<td>186 (51.1%)</td>
<td>173 (54.6%)</td>
<td>320 (63.5%)</td>
<td>957 (76.1%)</td>
</tr>
<tr>
<td>Glucocorticoid &gt;0 to 5 mg/day prednisone equivalent</td>
<td>600 (20.9%)</td>
<td>68 (32.2%)</td>
<td>93 (25.5%)</td>
<td>69 (21.8%)</td>
<td>149 (29.6%)</td>
<td>221 (17.6%)</td>
</tr>
<tr>
<td>--------------------------------------------------</td>
<td>------------</td>
<td>------------</td>
<td>------------</td>
<td>------------</td>
<td>------------</td>
<td>------------</td>
</tr>
<tr>
<td>Glucocorticoid 6-9 mg/day prednisone equivalent</td>
<td>68 (2.4%)</td>
<td>8 (3.8%)</td>
<td>10 (2.7%)</td>
<td>15 (4.7%)</td>
<td>12 (2.4%)</td>
<td>23 (1.8%)</td>
</tr>
<tr>
<td>Glucocorticoid ≥10 mg/day prednisone equivalent</td>
<td>142 (4.9%)</td>
<td>15 (7.1%)</td>
<td>28 (7.7%)</td>
<td>19 (6.0%)</td>
<td>23 (4.6%)</td>
<td>57 (4.5%)</td>
</tr>
<tr>
<td>Missing</td>
<td>303 (10.6%)</td>
<td>26 (11.0%)</td>
<td>47 (12.9%)</td>
<td>41 (12.9%)</td>
<td>59 (10.5%)</td>
<td>130 (9.4%)</td>
</tr>
</tbody>
</table>

**RA disease activity**

<table>
<thead>
<tr>
<th>Remission or low</th>
<th>1,949 (67.9%)</th>
<th>147 (74.2%)</th>
<th>226 (76.1%)</th>
<th>198 (77.3%)</th>
<th>388 (78.7%)</th>
<th>990 (81.5%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moderate or high</td>
<td>510 (17.8%)</td>
<td>51 (25.8%)</td>
<td>71 (23.9%)</td>
<td>58 (22.7%)</td>
<td>105 (21.3%)</td>
<td>225 (18.5%)</td>
</tr>
<tr>
<td>Missing</td>
<td>410 (14.3%)</td>
<td>39 (16.5%)</td>
<td>67 (18.4%)</td>
<td>61 (19.2%)</td>
<td>70 (12.4%)</td>
<td>173 (12.5%)</td>
</tr>
</tbody>
</table>

**Confirmed COVID-19**

| Confirmed COVID-19 | 2333 (81.3%) | 201 (84.8%) | 304 (83.5%) | 244 (77.0%) | 475 (84.4%) | 1109 (79.9%) |

n (%) presented unless otherwise specified.

*Comorbidity count included diabetes, lung disease, and chronic kidney disease.

^Interstitial lung disease, chronic obstructive pulmonary disease, asthma, or other lung disease.

COVID-19, Coronavirus Disease 2019; DMARDs, disease-modifying antirheumatic drugs; IL-6, interleukin-6; JAK, Janus kinase; RA, rheumatoid arthritis; SD, standard deviation, TNF, tumor necrosis factor, HCQ, hydroxychloroquine.
Table 2. Frequencies and proportions of outcomes in the ordinal COVID-19 severity scale according to baseline use of biologic or targeted synthetic disease-modifying antirheumatic drug for patients with rheumatoid arthritis at time of COVID-19 onset (n=2,869).

<table>
<thead>
<tr>
<th>COVID-19 severity scale</th>
<th>Overall n=2869</th>
<th>Abatacept n=237</th>
<th>Rituximab n=364</th>
<th>IL-6 inhibitors n=317</th>
<th>JAK inhibitors n=563</th>
<th>TNF inhibitors n=1388</th>
</tr>
</thead>
<tbody>
<tr>
<td>1) Not hospitalized</td>
<td>2256 (78.6%)</td>
<td>181 (76.4%)</td>
<td>210 (57.7%)</td>
<td>271 (85.5%)</td>
<td>409 (72.6%)</td>
<td>1185 (85.4%)</td>
</tr>
<tr>
<td>2) Hospitalized without oxygenation</td>
<td>137 (4.8%)</td>
<td>12 (5.1%)</td>
<td>20 (5.5%)</td>
<td>13 (4.1%)</td>
<td>28 (5.0%)</td>
<td>64 (4.6%)</td>
</tr>
<tr>
<td>3) Hospitalized with any oxygen or ventilation</td>
<td>319 (11.1%)</td>
<td>26 (11.0%)</td>
<td>80 (22.0%)</td>
<td>24 (7.6%)</td>
<td>86 (15.3%)</td>
<td>103 (7.4%)</td>
</tr>
<tr>
<td>4) Death</td>
<td>157 (5.5%)</td>
<td>18 (7.6%)</td>
<td>54 (14.8%)</td>
<td>9 (2.8%)</td>
<td>40 (7.1%)</td>
<td>36 (2.6%)</td>
</tr>
</tbody>
</table>

COVID-19, Coronavirus Disease 2019; IL-6, interleukin-6; JAK, Janus kinase; TNF, tumor necrosis factor.
Table 3. Results of primary and sensitivity analyses investigating the associations of baseline use of biologic or targeted synthetic disease-modifying antirheumatic drugs with COVID-19 severity (n=2,869).

<table>
<thead>
<tr>
<th></th>
<th>Abatacept</th>
<th>Rituximab</th>
<th>IL-6 inhibitors</th>
<th>JAK inhibitors</th>
<th>TNF inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR (95% CI)</td>
<td>p-value</td>
<td>OR (95% CI)</td>
<td>p-value</td>
<td>OR (95% CI)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unadjusted</td>
<td>1.88 (1.35, 2.63)</td>
<td>&lt;0.01</td>
<td>4.63 (3.60, 5.96)</td>
<td>&lt;0.01</td>
<td>1.00 (0.71, 1.41)</td>
</tr>
<tr>
<td>Age- and sex-adjusted</td>
<td>1.40 (0.99, 1.99)</td>
<td>0.06</td>
<td>4.45 (3.43, 5.77)</td>
<td>&lt;0.01</td>
<td>1.06 (0.68, 1.37)</td>
</tr>
<tr>
<td>Multivariable adjusted (primary analysis)</td>
<td>1.26 (0.88, 1.80)</td>
<td>0.21</td>
<td>4.15 (3.16, 5.44)</td>
<td>&lt;0.01</td>
<td>0.81 (0.56, 1.18)</td>
</tr>
<tr>
<td>Confirmed cases only*</td>
<td>1.14 (0.77, 1.68)</td>
<td>0.52</td>
<td>4.25 (3.17, 5.69)</td>
<td>&lt;0.01</td>
<td>0.74 (0.49, 1.11)</td>
</tr>
<tr>
<td>Excluding patients with ILD or cancer**</td>
<td>1.18 (0.79, 1.76)</td>
<td>0.43</td>
<td>4.34 (3.23, 5.82)</td>
<td>&lt;0.01</td>
<td>0.81 (0.54, 1.21)</td>
</tr>
<tr>
<td>Restricted to US and additionally adjusted for race***</td>
<td>1.16 (0.79, 1.69)</td>
<td>0.45</td>
<td>4.77 (3.57, 6.38)</td>
<td>&lt;0.01**</td>
<td>†</td>
</tr>
<tr>
<td>Propensity score matched****</td>
<td>1.60 (1.02, 2.51)</td>
<td>0.04</td>
<td>4.70 (3.31, 6.65)</td>
<td>&lt;0.01</td>
<td>0.76 (0.46, 1.23)</td>
</tr>
</tbody>
</table>

The effect size is the odds of being one level higher on the ordinal COVID-19 severity scale than the reference group (TNF inhibitor users).

Adjusted for age, sex, region, calendar time, obesity, smoking, concomitant csDMARD use, glucocorticoid use/dose, comorbidity count, hypertension/cardiovascular disease, interstitial lung disease, cancer, and rheumatoid arthritis disease activity except as otherwise indicated.

*n=2,333 in the analysis analyzing only confirmed COVID-19 cases.

**n= 2,704 in the analysis excluding ILD and cancer.

***n=868 in the US-only analysis.
****n for each pair of propensity-score matched analyses: ABA: 236 TNF: 1376; RTX: 364 TNFi: 1382; IL6i: 313 TNFi: 1387; JAKi: 560 TNFi: 1379
†Due to the small number of events in the covariate of race, this model could not be analyzed.
CI, confidence interval; COVID-19, Coronavirus Disease 2019; IL-6, interleukin-6; ILD, interstitial lung disease; JAK, Janus kinase; OR, odds ratio; TNFi, tumor necrosis factor inhibitors.
Table 4. Multivariable* odds ratios of biologic or targeted synthetic disease-modifying antirheumatic drugs at each binary level of the COVID-19 severity scale (n=2,869).

<table>
<thead>
<tr>
<th>COVID-19 outcome</th>
<th>Abatacept OR (95% CI)</th>
<th>p-value</th>
<th>Rituximab OR (95% CI)</th>
<th>p-value</th>
<th>IL-6 inhibitors OR (95% CI)</th>
<th>p-value</th>
<th>JAK inhibitors OR (95% CI)</th>
<th>p-value</th>
<th>TNF inhibitors OR (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospitalized</td>
<td>1.18 (0.76, 1.82)</td>
<td>0.47</td>
<td>4.53 (3.32, 6.18)</td>
<td>&lt;0.01</td>
<td>0.84 (0.53, 1.33)</td>
<td>0.45</td>
<td>2.40 (1.78, 3.24)</td>
<td>&lt;0.01</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>Hospitalized with oxygenation/ventilation or death</td>
<td>1.12 (0.70, 1.81)</td>
<td>0.63</td>
<td>2.87 (2.03, 4.06)</td>
<td>&lt;0.01</td>
<td>0.72 (0.43, 1.20)</td>
<td>0.20</td>
<td>1.55 (1.04, 2.18)</td>
<td>0.01</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>Death</td>
<td>1.46 (0.72, 2.89)</td>
<td>0.30</td>
<td>4.57 (3.32, 9.01)</td>
<td>&lt;0.01</td>
<td>1.13 (0.50, 2.59)</td>
<td>0.77</td>
<td>2.04 (1.58, 2.65)</td>
<td>&lt;0.01</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>Mechanical ventilation (restricted to only hospitalized patients; n = 613)</td>
<td>1.41 (0.94, 2.10)</td>
<td>0.09</td>
<td>4.05 (3.08, 5.33)</td>
<td>&lt;0.01</td>
<td>0.75 (0.51, 1.10)</td>
<td>0.14</td>
<td>2.03 (1.56, 2.62)</td>
<td>&lt;0.01</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>Mechanical ventilation or death</td>
<td>1.14 (0.78, 1.66)</td>
<td>0.50</td>
<td>4.44 (3.39, 5.82)</td>
<td>&lt;0.01</td>
<td>0.74 (0.50, 1.09)</td>
<td>0.12</td>
<td>2.02 (1.56, 2.61)</td>
<td>&lt;0.01</td>
<td>Ref</td>
<td></td>
</tr>
</tbody>
</table>

*Adjusted for age, sex, region, calendar time, obesity, smoking, concomitant csDMARD use, glucocorticoid use/dose, comorbidity count, hypertension/cardiovascular disease, interstitial lung disease, cancer, and rheumatoid arthritis disease activity
Supplementary Material for “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance Physician Registry” by Sparks JA, Wallace ZS, et al.

Supplementary Figure 1: Love plot for abatacept vs. TNF inhibitors.

Abatacept vs. TNF Love Plot
Supplementary Figure 2: Love plot for rituximab vs. TNF inhibitors.
Supplementary Figure 3: Love plot for IL-6 inhibitors vs. TNF inhibitors.
**Supplementary Figure 4**: Love plot for JAK inhibitors vs. TNF inhibitors.

![JAK vs. TNF Love Plot](image)

- **Distance**: Europe, North America, South America, Other
- **Age**:
- **Gender**: Ever Smoke, Never Smoke, Other, Obese
- **Disease Activity**: Comorbidity Count 0, Comorbidity Count 1, Comorbidity Count >2
- **Glucocorticoid Dose**: 0, 1-4, 6-9, >10
- **Any DMARD**: Jan. 1 2020-June 15, 2020, June 16, 2020- April 12, 2021

**Absolute Standardized Mean Difference**

---

https://mc.manuscriptcentral.com/ard
Supplementary Figure 5: Flow diagram illustrating analyzed sample for propensity score matching analyses.
**Supplementary Table 1.** Sensitivity analysis restricting to study period before or after June 16, 2021 and by North America or Europe.

<table>
<thead>
<tr>
<th></th>
<th>Abatacept</th>
<th>Rituximab</th>
<th>IL-6 inhibitors</th>
<th>JAK inhibitors</th>
<th>TNF inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR (95% CI)</td>
<td>p-value</td>
<td>OR (95% CI)</td>
<td>p-value</td>
<td>OR (95% CI)</td>
</tr>
<tr>
<td><strong>Restricted to North America</strong> (January 1, 2020 to June 15, 2020)</td>
<td>0.94 (0.40, 2.21)</td>
<td>0.89</td>
<td>3.95 (1.93, 8.06)</td>
<td>&lt;0.01</td>
<td>0.59 (0.18, 1.93)</td>
</tr>
<tr>
<td><strong>Restricted to Europe</strong> (January 1, 2020 to June 15, 2020)</td>
<td>1.11 (0.55, 2.23)</td>
<td>0.77</td>
<td>5.01 (3.10, 8.09)</td>
<td>&lt;0.01</td>
<td>1.00 (0.52, 1.92)</td>
</tr>
<tr>
<td><strong>Restricted to Europe</strong> (June 16, 2020-April 12, 2021)</td>
<td>1.45 (0.50, 4.23)</td>
<td>0.50</td>
<td>7.34 (3.94, 13.65)</td>
<td>&lt;0.01</td>
<td>0.28 (0.08, 1.02)</td>
</tr>
</tbody>
</table>

Adjusted for age, sex, region, obesity, smoking, concomitant csDMARD use, glucocorticoid use/dose, comorbidity count, hypertension/cardiovascular disease, interstitial lung disease, cancer, and rheumatoid arthritis disease activity except as otherwise indicated.

*There were too few cases to analyze North America June 16, 2020-April 12, 2021.
**Supplementary Table 2.** Frequencies and proportions of outcomes using a revised ordinal COVID-19 severity scale according to baseline use of biologic or targeted synthetic disease-modifying antirheumatic drug for patients with rheumatoid arthritis at time of COVID-19 onset (n=2,869).

<table>
<thead>
<tr>
<th>COVID-19 severity scale</th>
<th>Overall n=2,869</th>
<th>Abatacept n=237</th>
<th>Rituximab n=364</th>
<th>IL-6 inhibitors n=317</th>
<th>JAK inhibitors n=563</th>
<th>TNF inhibitors n=1388</th>
</tr>
</thead>
<tbody>
<tr>
<td>1) Not hospitalized</td>
<td>2256 (78.6%)</td>
<td>181 (76.4%)</td>
<td>210 (57.7%)</td>
<td>271 (85.5%)</td>
<td>409 (72.6%)</td>
<td>1185 (85.4%)</td>
</tr>
<tr>
<td>2) Hospitalized with or without oxygenation (but no mechanical ventilation)</td>
<td>428 (14.9%)</td>
<td>36 (11.0%)</td>
<td>91 (25.0%)</td>
<td>36 (11.4%)</td>
<td>108 (19.2%)</td>
<td>157 (11.3%)</td>
</tr>
<tr>
<td>3) Hospitalized with mechanical ventilation</td>
<td>28 (1.0%)</td>
<td>2 (0.8%)</td>
<td>9 (2.5%)</td>
<td>1 (0.32%)</td>
<td>6 (1.1%)</td>
<td>10 (0.7%)</td>
</tr>
<tr>
<td>4) Death</td>
<td>157 (5.5%)</td>
<td>18 (7.6%)</td>
<td>54 (14.8%)</td>
<td>9 (2.8%)</td>
<td>40 (7.1%)</td>
<td>36 (2.6%)</td>
</tr>
</tbody>
</table>
**Supplementary Table 3.** Associations of b/tsDMARD use with COVID-19 severity using a revised ordinal outcome scale.

<table>
<thead>
<tr>
<th></th>
<th>Abatacept</th>
<th>Rituximab</th>
<th>IL-6 inhibitors</th>
<th>JAK inhibitors</th>
<th>TNF inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>OR (95% CI)</strong></td>
<td>OR p-value</td>
<td>OR p-value</td>
<td>OR (95% CI)</td>
<td>p-value OR (95% CI)</td>
<td>p-value Ref</td>
</tr>
<tr>
<td>Unadjusted</td>
<td>1.87 (1.34, 2.61)</td>
<td>0.25</td>
<td>4.50 (3.50, 5.79)</td>
<td>&lt;0.01</td>
<td>0.99 (0.70, 1.40)</td>
</tr>
<tr>
<td>Multivariable Adjusted</td>
<td>1.24 (0.78, 2.19)</td>
<td>0.36</td>
<td>3.60 (3.40, 3.80)</td>
<td>&lt;0.01</td>
<td>0.83 (0.50, 1.37)</td>
</tr>
</tbody>
</table>

Adjusted for age, sex, region, calendar time, obesity, smoking, concomitant csDMARD use, glucocorticoid use/dose, comorbidity count, hypertension/cardiovascular disease, interstitial lung disease, cancer, and rheumatoid arthritis disease activity except as otherwise indicated.
Supplementary Table 4. Associations of b/tsDMARD use with COVID-19 severity using a revised ordinal outcome scale.

<table>
<thead>
<tr>
<th></th>
<th>Abatacept</th>
<th>Rituximab</th>
<th>IL-6 inhibitors</th>
<th>JAK inhibitors</th>
<th>TNF inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>OR (95% CI)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multivariable</td>
<td>1.24 (0.78, 2.19)</td>
<td>3.60 (3.40, 3.80)</td>
<td>0.83 (0.50, 1.37)</td>
<td>0.46 (1.11, 2.28)</td>
<td></td>
</tr>
<tr>
<td>adjusted (primary</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>analysis)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Excluding patients</td>
<td>1.24 (0.78, 1.96)</td>
<td>4.15 (2.95, 5.84)</td>
<td>0.66 (0.40, 1.07)</td>
<td>0.09 (1.25, 2.47)</td>
<td></td>
</tr>
<tr>
<td>with ILD or cancer*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Restricted to US</td>
<td>1.00 (0.48, 2.12)</td>
<td>3.82 (2.72, 5.37)</td>
<td>0.66 (0.40, 1.07)</td>
<td>0.09 (1.19, 2.35)</td>
<td></td>
</tr>
<tr>
<td>and additionally</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>adjusted for race**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Propensity score</td>
<td>1.72 (0.99, 2.98)</td>
<td>3.36 (2.11, 5.34)</td>
<td>0.68 (0.35, 1.32)</td>
<td>0.25 (1.01, 2.42)</td>
<td></td>
</tr>
<tr>
<td>matched***</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Adjusted for age, sex, region, calendar time, obesity, smoking, concomitant csDMARD use, glucocorticoid use/dose, comorbidity count, hypertension/cardiovascular disease, interstitial lung disease, cancer, and rheumatoid arthritis disease activity except as otherwise indicated.

*\( n=2,704 \) 1,563 in the analysis excluding ILD and cancer.
**\( n=622 \) 868 in the US-only analysis.
***\( n \) for each pair of propensity-score matched analyses: ABA: 236 TNF: 1376; RTX: 364 TNFi: 1382; IL6i: 313 TNFi: 1387; JAKi: 560 TNFi: 1379
CI, confidence interval; COVID-19, Coronavirus Disease 2019; IL-6, interleukin-6; ILD, interstitial lung disease; JAK, Janus kinase; OR, odds ratio; TNFi, tumor necrosis factor inhibitors.